Brief: Gain Therapeutics Says MDS-UPDRS Scores Remain Stable After 150 Days Of GT-2287 Treatment
26/05/2026 13:55
BRIEF-Gain Therapeutics Says MDS-UPDRS Scores Remain Stable After 150 Days Of GT-2287 Treatment May 26 (Reuters) - Gain Therapeutics Inc GANX.O:
GAIN THERAPEUTICS INC - MDS-UPDRS SCORES REMAIN STABLE AFTER 150 DAYS OF GT-2287 TREATMENT
GAIN THERAPEUTICS INC - 4.8 POINT DIFFERENCE IN MDS-UPDRS SCORES AT DAY 150 BETWEEN GLUSPH GROUPS
Source text: [ID:]
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall